CYP19A1 and breast carcinoma: In conclusion, our study offers further evidence that adjuvant therapy with aromatase inhibitors in women with breast cancer aged more than 50 years is associated with increased risk of heart failure and combined CV events, and such therapy probably amplifies the “intrinsic” CV risk of the patient.